Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 30/100

NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Key Takeaway: ClaimsFiler has announced that investors in NovoCure Limited have until August 18, 2023, to file lead plaintiff applications in a class action lawsuit against the company. The lawsuit arises from alleged violations of federal securities laws due to the company's failure to disclose important information. Despite reporting positive results from a Phase 3 clinical trial for its Tumor Treating Fields therapy, analysts noted the treatment was not aligned with current standards for lung cancer care. Following the announcement, NovoCure's shares experienced a notable decline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive results reported from the Phase 3 LUNAR clinical trial.
  • Therapy potentially offers benefits for patients not responding to standard treatments.

CONCERNS & RISKS

  • Class action lawsuit due to failure to disclose material information.
  • Share price fell significantly (43.04%) after trial results announcement.

Full Press Release Details

NEW ORLEANS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
NovoCure investors should visit us at https://claimsfiler.com/cases/nasdaq-nvcr/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 6, 2023, the Company announced “positive results” from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer; however, despite some positive aspects to the news, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors.
On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
The case is Bazzelle v. NovoCure Limited, et al., No. 23-cv-5146.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline for filing a claim against NovoCure?

The deadline to file lead plaintiff applications is August 18, 2023.

What is the Class Period for the NovoCure lawsuit?

The Class Period is from January 5, 2023, to June 5, 2023.

Where can NovoCure investors get legal help?

Investors can contact Kahn Swick & Foti, LLC for legal assistance.

What significant event occurred on June 6, 2023, regarding NovoCure?

NovoCure announced positive results from a clinical trial, but shares fell 43%.

How can I stay informed about securities class actions?

Register for free at ClaimsFiler.com to access relevant case information.

Last updated: Aug 2, 2023